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Our objective was to explore daily self-reported experience of axial spondyloarthritis (axSpA) flare 
based on data entered into the Project Nightingale smartphone app (www.projectnightingale.org), 
between 5th April 2018 - 1st April 2020.  
Methods 
Paired t-tests were conducted for mean_flare_on and mean_flare_off scores for each recorded 
variable. Mean estimated difference between flare and non-flare values for each variable was 
calculated with 95% confidence intervals (CI). Mean, standard deviation (SD) and range were 
reported for flare duration and frequency. Participants with ≥10 days of data entry were included for 
affinity propagation cluster analysis. Baseline characteristics and mean flare on versus flare off 
values were reported for each cluster. Welch’s t-test was used to assess differences between 
clusters. 
Results 
143/189 (75.7%) participants recorded at least 1 flare. Each flare lasted a mean of 4.30 days (SD 6.82 
days, range 1–78 days), a mean frequency of once every 35.32 days (SD 65.73, range 1-677 days). 
Significant relationships were identified between flare status and variable scores. Two clusters of 
participants were identified with distinct flare profiles. Group 1 experienced less severe worsening of 
symptoms during flare in comparison to Group 2 (p<0.01). However, they experienced significantly 
longer flare duration (7.2 versus 3.5 days, p<0.01); perhaps indicating a prolonged, yet less intense 
flare experience. Groups were similar in terms of flare frequency and clinical characteristics.  
Conclusions 
Two clusters of participants were identified with distinct flare experiences, but similar baseline 
clinical characteristics. Smartphone technologies capture subtle changes in disease experience, not 
currently considered in clinical practice.  
Key words  
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Key messages 
• Daily self-reported smartphone data identified two distinct clusters of people living with 
axSpA who had different flare experiences.  
• Despite differences in flare duration and symptoms, baseline clinical measures were similar 
between clusters.  
• Smartphone technologies capture subtle changes in disease experience not currently 




Axial spondyloarthritis (axSpA) is a chronic, inflammatory disease characterised by alternating 
periods of flare and more stable disease activity. Flares are often both unpredictable and 
debilitating, and a greater understanding of their nature and outcome is therefore important to both 
those living with axSpA and clinicians (1, 2). Over the last decade, although rapid advances have 
been made in terms of our understanding of axSpA, the natural history of the disease remains 
elusive. It has been hypothesised that the presence of early, severe disease flares (often associated 
with a worsening of symptoms or increased disease activity) may allow for early identification of 
people living with axSpA who may develop more severe disease (3-6). Indeed, severe flare has been 
identified as a poor prognostic factor in axSpA, particularly in early disease (4). It has therefore been 
suggested that early, aggressive treatment of severe flares in axSpA may improve long-term 
outcomes. 
Despite the frequent use of the concept “flare” within rheumatic condition terminology, an 
accepted, consistent definition of a flare does not yet exist for axSpA. In recent years, there have 
been attempts to define flare in both axSpA and other chronic rheumatic conditions such as 
rheumatoid arthritis, based upon validated composite indices, or through qualitative retrospective 
investigation of flare states (3, 7-9). Indeed, there is a growing interest in the concept of flare, and in 
characterising the lived experience behind this multidimensional phenomenon (1, 6, 7, 9-17). Such 
understanding is critical to better characterise the natural history of the condition and in future may 
facilitate optimisation/ personalisation of available treatments. The problematic nature of defining a 
flare in axSpA in part lies in the multifaceted, heterogenous nature of the disease. This problem was 
clearly demonstrated by Gossec and colleagues, whereby, in a preliminary attempt to classify flare, 
27 different flare definitions were identified among just 38 publications on axSpA (7).  
In prior studies investigating flare experience, those living with axSpA have often been asked to 
recall history of flare or prior experience of flare (3-6). However, this retrospective characterisation 
is subject to recall bias and may not provide an accurate picture of the lived day-to-day reality. 
Recently introduced smartphone technologies for the daily monitoring of disease symptoms and 
activity provide a unique insight into the daily experiences of individuals with chronic, fluctuating 
conditions (18-25). Such technologies may allow for a more accurate investigation of flare 
experience (12, 16, 17).  
In the present study, we conducted an exploratory analysis on a dataset of participants entering 
daily symptoms and behaviour into the Project Nightingale (uMotif) app 
(www.projectnightingale.org). Our objective was to explore individual’s self-reported experience of 
flare. We hoped to characterise the constituents of flare, the frequency and duration of flare, and 
whether people living with axSpA could be clustered based on their similar experiences. We then 
attempted to further characterise these clusters of participants, to provide detailed insights into 
potential distinct subtypes of flare experience.  
Methods 
Overview of Project Nightingale 
Since April 2018, people living with axSpA under the care of the Royal National Hospital for 
Rheumatic Diseases (RNHRD), Royal United Hospitals NHS Foundation Trust (RUH), Bath, have been 
eligible to participate in Project Nightingale. Project Nightingale was created to allow people living 
with axSpA to track daily symptoms and behaviour via their smartphone device and gain further 
insights into the nature of their condition.  
All participants are invited to track 10 variables via the uMotif smartphone app, including 8 fixed and 
2 optional variables. Fixed variables are tracked by all participants and include pain, mood, fatigue, 
sleep, stress, flare, recommended exercise, and anti-inflammatory use. While 2 optional variables 
are chosen by each participant from the following: caffeine intake, hot flushes, adherence to 
medication, screen time, confidence in self-management, eyesight, hydration, chest pain, flare of 
psoriasis, impact of menstrual cycle, red painful eyes, smoking habits and blood in stool. The 
variables and associated scales were designed by the lead consultant for axSpA at the RNHRD to 
optimise clinical relevance, following years of regular, detailed and empathetic interaction with 
people living with axSpA.  
Participants are asked how they are feeling each day via the app. They rate each variable on a 5-
point Likert scale. The interface for recording each outcome is displayed as a flower-like 
visualisation, whereby each petal represents one of the ten tracking variables (Supplementary Figure 
1). Participants are required to drag their finger from the centre of the flower to the outer edge of 
each petal to record their symptoms. For each variable, a score of 1 equates to the less healthy or 
desirable outcome, whereas a score of 5 represents the most healthy/positive outcome or 
behaviour. For example, for pain: 1=debilitating pain; 5=no pain. The flower-motif recording 
interface acts as a visual metaphor, whereby a full flower represents the most healthy or optimal 
outcomes. Participants receive daily reminders for data entry as a notification to their smartphone if 
data has not already been entered. In the uMotif app settings, participants can choose to opt out of 
reminders or alter their time and frequency.  
Data collection 
For the present study, we utilised smartphone data collected via the Project Nightingale (uMotif) 
app between 5th April 2018 and 1st April 2020. South West - Central Bristol UK local research ethics 
committee for National Health Service research approved the study, and all patients provided 
written informed consent (The Bath Spondyloarthritis Biobank; REC reference: 13/SW/0096). Clinical 
data was collected based on routine assessment at the RNHRD. Baseline measures were extracted at 
visit date closest to Project Nightingale registration – restricted to visit dates within 90 days of 
Project Nightingale registration. Data from participants’ wearable and smart device applications 
were downloaded regularly and incorporated into the patient record.  
Statistical methods 
For participants with at least one flare and non-flare set of recorded variables, data was aggregated 
to one row per participant, containing mean values with and without flare for each petal variable. 
For example, Participant 1 would have an 'average_pain_flare_on' feature and an 
'average_pain_flare_off' feature for each variable. Paired t-tests were conducted for each variable, 
to investigate which variables correlated with flare status. The difference between the 'flare_on' and 
'flare_off' features were taken for each pair to create a set of 'difference' features, to capture the 
effect of a flare on each petal variable for each participant. The mean estimated difference between 
flare and non-flare values for each variable was calculated with 95% confidence intervals (CI). The 
mean, standard deviation (SD) and range were reported for flare duration and flare frequency. For 
the flare duration calculation, two logged periods of flare occurring within three days were to be 
considered as one period of flare if missing one day of data between entries. 
For the cluster analysis, Project Nightingale participants with <10 days of data entry were excluded. 
'Difference' features for each variable for each participant were normalized to between -1 and 1, 
and then used for clustering. Affinity propagation was used as the clustering algorithm via the 
'apcluster' R package (26). negDistMat(r=2) was used for the similarity matrix, squaring the distance 
measures between participants to calculate similarities (27). q=0 was used to minimize the number 
of clusters found. Given the size of the dataset (129 participants), it was decided to lower the 
number of clusters in order to achieve a meaningful sample size for each cluster (28).  
Baseline characteristics and mean flare on versus flare off values were reported for each cluster. 
Welch’s t-test was used to assess differences between clusters. 
Patient and public involvement (PPI) statement 
Project Nightingale was established through a strong collaboration between the RNHRD (RUH, Bath) 
and consultant Dr Raj Sengupta, engagement with relevant stakeholders (people living with 
axSpA/HCPs), the charity White Swan and the Bath Institute for Rheumatic Diseases (BIRD). This has 
facilitated PPI from project initiation. Petal tracking variables were determined by Dr Raj Sengupta, 
based on decades of clinical experience and interactions with people living with axSpA. Additional 
optional variables were also added to the scope, based on patient feedback at Project Nightingale 
information days. These regular Project Nightingale & axSpA information days organised by BIRD 
have facilitated patient-HCP-researcher discussion, knowledge exchange, participant feedback and 
dissemination of results. Such interactions/collaboration have informed advancement of future 
Project Nightingale research plans and app innovation.  
PPI has been maintained during the COVID-19 pandemic via regular Project Nightingale patient-HCP-
researcher discussions during the well-established RNHRD axSpA rehabilitation course. A Project 
Nightingale BIRD podcast episode and Facebook Live event with the National Axial Spondyloarthritis 
Society have also facilitated PPI. The Project Nightingale blog and twitter has facilitated regular 
research updates/ dissemination of results to the wider axSpA community. This has allowed for 
further patient participation and discussion of experiences (29, 30).  
Results 
Between 5th April 2018 and 1st April 2020, 189 patients consented for research and logged a mean of 
156.78 (SD=199.60) days of data (range=1 - 711 days). 143/189 (75.7%) participants recorded at 
least 1 flare, with 1,349 flares recorded in total. Each flare lasted a mean of 4.30 days (SD 6.82 days, 
range 1–78 days), with a mean frequency per participant of once every 35.32 days (SD 65.73, range 
1-677 days). Significant relationships were identified between flare status and variable scores (Table 
1). Small but significant (p<0.01) estimated differences were found between flare and non-flare 
scores for pain, fatigue, sleep quality, exercise, mood, anti-inflammatory use, stress, confidence in 
self-management and chest pain. 
Between 5th April 2018 and 1st April 2020, 129 patients had registered for participation in Project 
Nightingale and provided 10 or more days of data entry suitable for the cluster analysis. Two clusters 
of participants were identified based on distinct profiles of uMotif petal symptom scores during 
flares, using non-flare scores as a baseline comparator (Figure 1, Table 2). Group 1 appeared to 
experience less severe worsening of pain, fatigue, sleep, mood and stress during flare (versus non-
flare) in comparison to Group 2 (p<0.01). However, this group also experienced significantly longer 
flare duration (7.2 versus 3.5 days, p<0.01) (Supplementary Table 1); perhaps indicating a more 
prolonged, yet less intense flare experience. Although not reaching significance due to small sample 
size, Group 2 also demonstrated a more severe decrease (worsening) in score for chest pain, 
confidence in self-management, eyesight, flare of psoriasis, impact of menstrual cycle and screen 
time. Changes in anti-inflammatory use and recommended exercise during flare versus non-flare 
appeared similar between the two groups; perhaps suggesting similar behaviours while attempting 
to resolve flares.  
Group 2 reported slightly (petal score difference of <0.5) better sleep quality (p=0.022) and very 
slightly higher levels of recommended exercise (p=0.026) than Group 1 when not in flare; despite 
worse scores for pain (p=0.043), fatigue (p=0.001), mood (p=0.031) and stress (p<0.001) during flare 
(Table 3). No significant differences were found between groups for pain, fatigue, mood, anti-
inflammatory use or stress when not in flare. 
The baseline (at Project Nightingale registration) characteristics of participants in each cluster group 
are presented in Table 4. Both groups were similar in terms of gender, HLA-B27 status and other 
clinical characteristics such as spinal mobility (BASMI). However, Group 1 had a significantly greater 
proportion of smokers (p<0.001). Group 2 had a significantly greater proportion of people who had 
never smoked (p<0.05). 
Discussion 
To our knowledge, this is the first study to investigate, characterise and group daily self-reported 
flare profiles in people with axSpA, utilising a smartphone application and remote data collection. 
Two distinct clusters of participants were identified. Whereby, one group reported significantly 
shorter flare duration (p<0.01), however experienced a significantly greater worsening of pain, 
fatigue, mood, sleep and stress during flare (p<0.01). Perhaps indicating a shorter, although more 
intense, flare experience. Number and frequency of flares were similar between clusters. As were 
baseline clinical measures such as BASMI, BASDAI, BASFI and quality of life (measured through 
ASQoL). Smartphone technologies therefore have the potential to capture subtle, potentially critical 
changes in disease activity that are not currently considered in clinical practice. Although the long-
term significance of these is yet to be explored, such work is planned in our future research agenda. 
Furthermore, the study of such daily self-report data may in future allow for prediction of flare 
based on patterns of symptoms/behaviour or enable a greater understanding of behaviours that 
lead to earlier resolution of flare. This may facilitate earlier targeting and prevention of flares to 
reduce flare frequency and duration – to ultimately improve quality of life for patients. 
Prior qualitative work by Brophy and Calin in 2002 also identified two types of flare, localised and 
generalised, based on group discussions with 214 patients, over the period of one year (3). All 
participants had experienced a localised flare, involving pain and immobility in one area, sometimes 
accompanied by fatigue and emotional symptoms. In contrast, only 40% (85/214) of participants had 
experienced generalised flares, involving the whole body. This was described as an infrequent event 
whereby all symptoms were experienced to the extreme. Individuals reporting generalised flares 
described the localised flares as not a “true” flare – perceiving localised increases in disease activity 
as incomparable to the crippling, acute and devastating phenomenon of a whole-body flare. Similar 
experiences of localised (minor) or generalised (major) flares have been characterised in later 
studies also – by Stone and colleagues in 2008 (6) and a follow-up study in 2010 (5). In the present 
study, we were unable to determine the location of flares. However, our results appear broadly 
consistent in terms of one group of patients experiencing more intense, debilitating flares, with 
greater changes in symptoms such as pain, fatigue, mood, sleep and stress. In the present study, this 
group experiencing more severe flares again appeared to involve the minority of participants (26% 
of participants in the present study, 33/129).  
Our average flare duration may appear less than previously reported. In 2002, Brophy and Calin 
described the majority of flares as short-term (days to weeks) – broadly in agreement with the 
present study (3). However, in 2010, Cooksey and colleagues reported a mean flare duration of 2.4 
weeks (5). In comparison to an average duration of 7.2 and 3.5 days for Group 1 and Group 2 
respectively in the present study. This is likely because our flare duration calculation was quite strict, 
in that a flare required subsequent days of uMotif flare entries to be considered as 'continued'. Just 
1 day of missing data was permitted. For example, if a participant recorded a flare on a Monday and 
Wednesday but with missing data on Tuesday, this would be recorded as a single period of flare. 
However, if a participant recorded a flare on a Monday and Thursday with 2 missing days of data, 
this would be considered as two separate periods of flare. This was defined in alignment with a more 
recent study by Jacquemin and colleagues, whereby the majority of reported flares lasted ≤3 days 
(14).  However, this definition may have considerably underestimated the flare duration in the 
present study. The past 10-20 years have shown dramatic advances in our understanding of axSpA, 
including the introduction of the widespread use of biologics, improved treatment strategies and a 
change in definition of disease (to include non-radiographic axSpA in addition to ankylosing 
spondylitis). Therefore, this may have contributed to the differences in flare duration seen in the 
present study and the study by Jacquemin and colleagues (2017). Indeed, both earlier studies 
(Brophy and Calin, Cooksey and colleagues) included only people with ankylosing spondylitis, not 
non-radiographic axSpA also, perhaps further contributing to the disparity in flare duration.  
It is also important to note that, despite short flare duration in the present study, the mean flare 
frequency per participant was once every 35.32 days (SD 65.73). This suggests that there is still a 
need for optimisation/personalisation of treatments in axSpA in order to reduce the frequency of 
debilitating flare, and potential associated poor clinical outcomes and work impairment (4, 6, 31, 
32).  
Beyond the importance of flare characterisation in clinical practice, flare also represents an 
important endpoint to consider in clinical trials. As a potential indicator of disease severity, flare 
assessment is vital to understanding disease status or treatment efficacy and is of particular 
importance in tapering or discontinuation trials (33-36). There has recently been an attempt to 
quantify a single definition of flare based on validated composite indices for the purpose of 
harmonising trial designs in axSpA (7, 37). However, it is important to distinguish between the 
necessarily stricter, arbitrarily homogenous definition of flare that is required in clinical trials, versus 
the highly variable, highly individualised flare experience of those living with axSpA. In clinical 
practice, in order to move towards optimisation and personalisation of treatments, the latter 
definition as explored in the present study may arguably be of greater significance. This may be 
supported by the fact that in the present study, although Group 2 reported significantly worse flare 
experience via the uMotif app, we found no significant difference in baseline spinal mobility, disease 
activity or function as measured by validated BASMI, BASDAI and BASFI measures between the two 
groups. Highlighting the power of smartphone technologies to capture potentially critical 
fluctuations in disease severity that are too subtle to be observed by traditional, infrequent 
measurement of existing validated indices. Indeed, future integration of daily self-reported health 
data into the electronic health record may allow for greater optimisation and personalisation of 
treatment outcomes, through more accurate reporting of disease experience (38). 
A limitation of the present study is with regard to adherence. Upon registration, participants were 
encouraged to enter data every day. However, they were told that any data entry may be useful, 
including restarting after inactive periods. Prior qualitative and quantitative evidence suggests that 
patients with worse disease experience in axSpA may be more likely to adhere to self-tracking 
behaviour (39). Therefore, our results may be biased towards those with more severe disease. 
Similar results have been reported in the literature for other inflammatory, rheumatic conditions 
such as rheumatoid arthritis; whereby, it has been suggested that patients may primarily use self-
tracking apps in the case of impending flares (40).  
Another potential source of bias in the present study is that the RNHRD is a tertiary hospital, 
receiving both local and specialist referrals. Therefore, our cohort may be more severely affected by 
axSpA or less likely to experience a down-period between flares. However, both our own data and 
data from prior studies from the RNHRD suggest that our cohort of patients reflect the full spectrum 
of axSpA disease (6, 41). For example, the population included in the present study showed a range 
of BASDAI scores from 0-8.6, and BASMI scores ranging from 0-7.8. Disease duration (from age of 
onset to age at study consent) ranged from 4 years to 68 years. Furthermore, it is now common 
practice and recommended for General Practitioners to refer all suspected axSpA diagnoses to a 
specialist centre (42). 
Conclusions 
The results of the present study yield novel insights into the characterisation of flares in axSpA. 
Significant relationships were identified between a variety of patient-reported symptoms and flare, 
including variables that to our knowledge, have not yet been explored in axSpA. Clustering of daily 
self-reported symptom data has identified two clusters of people with axSpA who have distinct flare 
profiles. One group appears to experience significantly longer flare duration. However, this group 
also experiences less dramatic worsening of pain, fatigue, sleep, mood and stress during flare in 
comparison to non-flare. Although we observed differences between the two groups in terms of 
flare experience, clinical differences in BASMI, BASDAI and BASFI were not identified. Highlighting 
the potential of smartphone technologies to capture subtle, potentially critical changes in disease 
activity that are not currently considered in clinical practice.  
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Tables and figures 
 
Table 1. Paired t-tests: flare vs. non-flare scores for each variable 
Estimated 
difference^ 
p-value 95% CI (lower 
limit) 
95% CI (upper 
limit) 
N Variable 
-0.788* 0.000 -0.898 -0.679 143 Pain 
-0.599* 0.000 -0.706 -0.491 143 Fatigue 
-0.228* 0.000 -0.303 -0.153 142 Sleep quality 
-0.296* 0.000 -0.416 -0.177 143 Recommended exercise 
-0.381* 0.000 -0.463 -0.298 143 Mood 
0.140* 0.000 0.090 0.191 143 Anti-inflammatory use 
-0.343* 0.000 -0.459 -0.228 143 Stress 
-0.038 0.348 -0.119 0.043 59 Caffeine intake 
-0.404 0.012 -0.709 -0.100 19 Hot flushes 
-0.018 0.685 -0.106 0.071 26 Adherence 
-0.289 0.092 -0.630 0.053 18 Screen time 
-0.500* 0.000 -0.693 -0.307 36 Confidence in self-
management 
-0.123 0.121 -0.281 0.035 24 Eyesight 
-0.136 0.123 -0.311 0.038 51 Hydration 
-0.419* 0.006 -0.707 -0.131 28 Chest pain 
-0.024 0.681 -0.238 0.191 3 Flare of psoriasis 
-0.310 0.175 -0.781 0.161 13 Menstrual cycle 
0.101 0.599 -0.345 0.547 7 Red painful eyes 
0.132 0.704 -1.163 1.427 3 Smoking today 
0.224 0.371 -1.655 2.104 2 Blood in stool 
N= number of patients with both a flare and non-flare entry for each variable; CI=confidence interval. Higher variable scores 
indicate more positive outcomes (e.g. a higher pain score indicates less pain).  
*p<0.01. 
^Estimated difference between flare and non-flare entries (e.g. on average, the mean pain score of a flare entry is 0.67 
[0.56– 0.78 CI] less than a non-flare entry). 
 
Figure 1. Differences (normalised to [-1,1]) in petal values between two clusters of patients recording self-reported flare in 
the Project Nightingale (uMotif) app 
 
Table 2. Absolute differences in petal values between flare and no flare values for two clusters of patients recording self-






Difference* N Difference* N 
Pain_flare_on_diff -0.694 96 -0.984 33 0.007 
Fatigue_flare_on_diff -0.368 96 -1.111 33 0.000 
Sleep.Quality_flare_on_diff -0.151 96 -0.438 33 0.000 
Recommended.Exercise_flare_on_diff -0.274 96 -0.422 33 0.300 
Mood_flare_on_diff -0.251 96 -0.800 33 0.000 
Anti.inflamatory_flare_on_diff 0.131 96 0.128 33 0.960 
Stress_flare_on_diff -0.101 96 -0.980 33 0.000 
Caffeine.intake_flare_on_diff -0.015 43 -0.122 11 NA 
Hot.flushes_flare_on_diff -0.408 17 -0.348 1 NA 
Adherence_flare_on_diff -0.008 13 -0.032 11 NA 
Screen.time_flare_on_diff -0.124 12 -0.619 6 NA 
Confidence.in.self.management_flare_on_diff -0.330 23 -0.779 9 NA 
Eyesight_flare_on_diff -0.077 18 -0.362 4 NA 
Hydration_flare_on_diff -0.103 32 0.046 14 NA 
Chest.pain_flare_on_diff -0.227 19 -0.956 4 NA 
Flare.of.psoriasis_flare_on_diff -0.024 3 NA 0 NA 
Menstrual.cycle_flare_on_diff -0.115 8 -0.399 2 NA 
Red..painful.eyes_flare_on_diff -0.094 4 0.043 2 NA 
Smoking.today_flare_on_diff 0.132 3 NA 0 NA 
Blood.in.stool_flare_on_diff NA 0 0.224 2 NA 
*Absolute difference from baseline (non-flare) 
NA=sample size too small to determine statistical significance 
Table 3. Mean flare on and flare off values for two clusters of patients recording self-reported flare in the Project 






Mean SD Mean SD 
Flare on 
     
Pain 3.083 0.638 2.850 0.529 0.043 
Fatigue 3.077 0.967 2.555 0.614 0.001 
Sleep Quality 3.177 0.594 3.192 0.668 0.910 
Recommended Exercise 3.219 1.152 3.513 0.994 0.166 
Mood 3.051 0.799 2.693 0.801 0.031 
Anti-inflammatory Use 0.552 0.408 0.575 0.373 0.770 
Stress 3.875 0.720 3.070 0.902 0.000 
Flare off 
     
Pain 3.777 0.581 3.834 0.590 0.635 
Fatigue 3.445 0.805 3.666 0.657 0.122 
Sleep Quality 3.328 0.545 3.630 0.657 0.022 
Recommended Exercise 3.494 1.019 3.934 0.934 0.026 
Mood 3.302 0.740 3.494 0.708 0.191 
Anti-inflammatory Use 0.421 0.402 0.447 0.398 0.753 
Stress 3.977 0.657 4.049 0.716 0.609 
 
Table 4. Baseline* characteristics of two clusters of patients recording self-reported flare in the Project Nightingale (uMotif) 
app 





Baseline* values Mean SD N Mean SD N p-value 
Mean (SD) BASMI score 3.173 2.069 59 3.533 2.082 18 NA 
Mean (SD) BASDAI score 3.680 1.733 70 3.852 2.081 21 0.732 
Mean (SD) BASFI score 3.627 2.568 66 3.715 2.214 20 0.882 
Mean (SD) EQ-5D 0.618 0.191 53 0.659 0.240 20 0.499 
        Mean (SD) EQ-5D 
        Pain and Discomfort 
2.585 0.663 53 2.400 0.940 20 0.427 
        Mean (SD) EQ-5D 
        Anxiety and Depression 
1.906 1.005 53 1.600 0.754 20 0.167 
Mean (SD) Patient-global 4.018 2.057 57 3.429 2.420 21 0.329 
Mean (SD) ASQoL 8.060 4.716 59 7.935 5.234 21 0.924 
Mean (SD) work productivity 
impairment 
3.640 2.691 25 4.000 3.162 13 NA 
Mean (SD) activity impairment 4.240 2.722 50 3.950 2.964 20 0.708 
Proportion of employed 0.592 0.497 49 0.650 0.489 20 0.658 
Proportion of females 0.354 0.481 96 0.303 0.467 33 0.592 
Proportion of males 0.646 0.481 96 0.697 0.467 33 0.592 
Proportion HLA-B27 +ve 0.818 0.388 88 0.813 0.397 32 0.945 
Proportion of current smokers 0.154 0.364 65 0.000 0.000 21 0.001 
Proportion of ex-smokers 0.431 0.499 65 0.333 0.483 21 0.431 
Proportion of non-smokers 
(never smoked) 
0.415 0.497 65 0.667 0.483 21 0.047 
Proportion ever treated with 
bDMARDs 
0.427 0.497 96 0.515 0.508 33 0.391 
Proportion with CWP  0.188 0.392 96 0.333 0.479 33 0.121 
*at visit date closest to Project Nightingale registration – restricted to visit dates within 90 days of Project Nightingale 
registration date 
SD=standard deviation; CWP=chronic widespread pain 
 
Supplementary material 
Supplementary Figure 1A & 1B. Screenshots from the Project Nightingale smartphone app - daily completion of the motif 
 
 
Supplementary Table 1. Flare characteristics of two clusters of patients recording self-reported flare in the Project 






Mean SD N Mean SD N 
Number of flares 10.385 12.267 96 10.091 13.689 33 0.913 
Mean number of active days 
(days reporting symptoms in 
the app) 
223.906 210.692 96 188.818 201.750 33 0.398 
Mean flare frequency^ 0.072 0.069 96 0.091 0.084 33 0.249 
Mean flare duration (no. of 
days) 
7.208 10.188 96 3.530 2.756 33 0.002 
^ Flare frequency reported as a proportion of each participants' number of active days. 
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